AlphAIalphai — Financial news for AI agents
BenzingaNOV 42 min read$DORM

Sell Alert: David Hession Cashes Out $1.69M In Dorman Products Stock - Dorman Products (NASDAQ:DORM)

On November 3, a recent SEC filing unveiled that David Hession, SVP and CFO at Dorman Products ( NASDAQ:DORM ) made an insider sell. What Happened: After conducting a thorough analysis, Hession sold 12,493 shares of Dorman Products. This information was disclosed in a Form 4 filing with the ...

Original reporting
Benzinga · Benzinga Insights
Published Nov 4, 2025, 3:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 4, 2025, 4:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Sell Alert: David Hession Cashes Out $1.69M In Dorman Products Stock - Dorman Products (NASDAQ:DORM) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$DORMNeutralLow
01

Why it matters

While insider sales can sometimes signal caution, they are not definitive. The low relevance score suggests limited immediate market impact.

02

Market read

The event has minimal impact on the stock's short-term trading dynamics but warrants monitoring for future insider activity.

03

What to watch

Lack of recent earnings data or guidance; market conditions and overall industry trends should be considered.

Timing: short-term

Background

David Hession, SVP and CFO of Dorman Products, sold 12,493 shares as disclosed in SEC Form 4 on November 3, 2025.

Company-level read

Ticker impact

$DORMNeutralMedium confidence
Context

Recent insider sell by SVP and CFO

Expected impact

Minimal to no immediate impact on stock price; potential slight downward pressure if viewed negatively by the market.

Evidence & confidence

Insider sales are common and can be motivated by personal reasons; without additional context, their predictive power is limited.

Market effects

Sector

The sale does not indicate sector-wide issues; manufacturing sector remains stable.

Regional

Limited regional impact; company-specific event.

Global

Negligible

Counterpoint

What could challenge this read

Insider sales might be routine and not indicative of future performance; could be personal financial planning.

Key entities

  • Company
    Dorman Products

    Manufacturer of automotive replacement parts.

Read at source← All news

Related articles

AUG 11
$DORMMedAI 8/10

Dorman Products (DORM) Q2 2026 Earnings Call Transcript

Dorman Products (DORM) reported Q2 2026 net sales of $544.6 million (+0.7%) and adjusted diluted EPS of $3.08 (+50%), helped by a $1.18 per share IEEPA tariff refund. Adjusted gross margin rose to 46.1%. FY2026 guidance: net sales growth 3% to 5% and adjusted EPS $8.50 to $8.80.

fool.com6 min
AUG 3
$DORMMedAI 8/10

Dorman Products Q2 net sales rise to $544.6 million

Dorman Products reported Q2 2026 net sales of $544.6 million, up 0.7% from $541.0 million. Net income rose to $87.8 million and diluted EPS increased 53% to $2.93, aided by IEEPA tariff cost recovery, according to the company. Operating cash flow was $152.6 million; it repurchased $47 million of shares. Updated guidance: net sales growth 3% to 5% and EPS $7.93 to $8.23.

quiverquant.com5 min
AUG 3
$DORMMed

Dorman Products, Inc. (DORM): Results of Operations and Financial Condition

Dorman Products, Inc. (DORM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dorman Products, Inc. Reports Second Quarter 2026 Results; Updates 2026 Guidance Highlights (All comparisons are to the prior year period unless otherwise noted) : • Net sales of $544.6 million for the quarter, up 0.7% • Diluted earnings per share (“EPS”) of $2.93, u

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min